Is Abbott Laboratories stock a Buy, Sell or Hold?
Abbott Laboratories stock has received a consensus rating of buy. The average rating score is A1 and is based on 50 buy ratings, 6 hold ratings, and 0 sell ratings.What was the 52-week low for Abbott Laboratories stock?
The low in the last 52 weeks of Abbott Laboratories stock was 93.27. According to the current price, Abbott Laboratories is 104.01% away from the 52-week low.What was the 52-week high for Abbott Laboratories stock?
The high in the last 52 weeks of Abbott Laboratories stock was 124.35. According to the current price, Abbott Laboratories is 78.01% away from the 52-week high.What are analysts forecasts for Abbott Laboratories stock?
The 56 analysts offering price forecasts for Abbott Laboratories have a median target of 130.00, with a high estimate of 157.00 and a low estimate of 105.00. The median estimate represents a 74.62 difference from the last price of 97.01.Abbott Laboratories Stock Snapshot
96.99
Bid
5,300.00
Bid Size
97.01
Ask
15,500.00
Ask Size
3/17/2023
Date
4:15 PM
Time
6.24 M
Volume
99.03
Prev. Close
98.99
Open
170.05 B
Market Cap
1.74 B
Number of Shares
96.51
Day Low
99.03
Day High
97.01
93.27
52 Week Low
124.35
52 Week High
97.01
1.96
Dividend
1.99
Dividend Yield
20.61
P/E Ratio
99.13
Free Float in %
4.40
EPS 2023
22.28
Book Value per Share
6.12
Cash Flow per Share
Abbott Laboratories News More News
Abbott Laboratories Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Abbott Laboratories Analyst Data
Total Analysts: 56
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 105.00
Median: 130.00
Highest: 157.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Abbott Laboratories Analyst Opinions
- All
- Buy
- Hold
- Sell
| 01/27/23 | Barclays Capital | Maintained Buy | $125 | ||
| 01/26/23 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $125 | ||
| 01/26/23 | Raymond James Financial, Inc. | Maintained Buy | $123 | ||
| 01/26/23 | Bernstein | Maintained Buy | $132 | ||
| 01/24/23 | Mizuho | Maintained Hold | $110 | ||
| 01/06/23 | Morgan Stanley | Maintained Buy | $133 | ||
| 12/12/22 | Citigroup Corp. | Maintained Buy | $125 | ||
| 10/26/22 | Mizuho | Maintained Hold | $105 | ||
| 10/21/22 | Barclays Capital | Maintained Buy | $114 | ||
| 10/21/22 | Raymond James Financial, Inc. | Maintained Buy | $109 | ||
| 10/20/22 | Morgan Stanley | Maintained Buy | $117 | ||
| 10/20/22 | RBC Capital Markets | Maintained Buy | $126 | ||
| 10/18/22 | Barclays Capital | Maintained Buy | $118 | ||
| 10/17/22 | BTIG Research | Maintained Buy | $123 | ||
| 10/12/22 | Jefferies & Company Inc. | Maintained Hold | $110 | ||
| 10/11/22 | Morgan Stanley | Maintained Buy | $126 | ||
| 10/10/22 | Wells Fargo & Co | Maintained Buy | $140 | ||
| 07/27/22 | UBS | Maintained Buy | $128 | ||
| 07/21/22 | RBC Capital Markets | Maintained Buy | $132 | ||
| 07/21/22 | Citigroup Corp. | Maintained Buy | $123 | ||
| 07/21/22 | Morgan Stanley | Maintained Buy | $132 | ||
| 07/18/22 | BTIG Research | Maintained Buy | $126 | ||
| 07/18/22 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $126 | ||
| 07/15/22 | Morgan Stanley | Maintained Buy | $134 | ||
| 07/15/22 | Raymond James Financial, Inc. | Maintained Buy | $117 | ||
| 07/06/22 | Wolfe Research | Maintained Sell | |||
| 06/24/22 | BTIG Research | Maintained Buy | $130 | ||
| 06/07/22 | Morgan Stanley | Maintained Buy | $145 | ||
| 05/17/22 | Citigroup Corp. | Maintained Buy | $125 | ||
| 04/21/22 | Raymond James Financial, Inc. | Maintained Buy | $135 | ||
| 04/21/22 | RBC Capital Markets | Maintained Buy | $143 | ||
| 04/08/22 | Wells Fargo & Co | Maintained Buy | $150 | ||
| 01/27/22 | Morgan Stanley | Maintained Buy | $151 | ||
| 01/27/22 | Raymond James Financial, Inc. | Maintained Buy | $143 | ||
| 01/07/22 | Morgan Stanley | Maintained Buy | $157 | ||
| 12/22/21 | Raymond James Financial, Inc. | Maintained Buy | $150 | ||
| 12/10/21 | RBC Capital Markets | Maintained Buy | $146 | ||
| 10/27/21 | Atlantic Equities | Upgraded to Buy | $144 | ||
| 10/21/21 | Morgan Stanley | Maintained Buy | $146 | ||
| 10/21/21 | Raymond James Financial, Inc. | Maintained Buy | $134 | ||
| 10/21/21 | SVB Leerink | Maintained Hold | $140 | ||
| 08/31/21 | BTIG Research | Maintained Buy | $136 | ||
| 07/23/21 | Morgan Stanley | Maintained Buy | $136 | ||
| 07/23/21 | Credit Suisse | Maintained Buy | $130 | ||
| 07/23/21 | Raymond James Financial, Inc. | Maintained Buy | $128 | ||
| 07/20/21 | SVB Leerink | Maintained Hold | $128 | ||
| 07/12/21 | Wells Fargo & Co | Maintained Buy | $135 | ||
| 06/02/21 | Credit Suisse | Maintained Buy | $120 | ||
| 06/02/21 | BTIG Research | Maintained Buy | $120 | ||
| 06/02/21 | Morgan Stanley | Maintained Buy | $126 |
Abbott Laboratories Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
| Revenue | 39,997 | 42,175 | 44,938 | 48,147 | 51,219 |
| Dividend | 1.96 | 2.09 | 2.40 | 2.53 | - |
| Dividend Yield (in %) | 1.99 % | 2.12 % | 2.44 % | 2.57 % | - |
| EPS | 4.40 | 4.86 | - | 5.91 | 6.42 |
| P/E Ratio | 22.28 | 20.19 | 19.42 | 16.60 | 15.28 |
| EBIT | 8,877 | 9,844 | 10,821 | 11,842 | 12,975 |
| EBITDA | 10,264 | 11,650 | 12,688 | 13,980 | 17,333 |
| Net Profit | 7,724 | 8,485 | 9,340 | 10,327 | 11,260 |
| Net Profit Adjusted | 7,724 | 8,485 | 9,340 | 10,327 | 11,260 |
| Pre-Tax Profit | 8,996 | 9,895 | 10,851 | 11,838 | 13,093 |
| Net Profit (Adjusted) | 6,689 | 7,675 | 8,970 | 11,031 | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | 6.20 | - |
| EPS (GAAP) | 3.27 | 3.76 | 4.34 | 5.25 | - |
| Gross Income | 22,427 | 23,978 | 25,735 | 27,526 | 29,572 |
| Cash Flow from Investing | -2,016 | -2,384 | -2,667 | -2,718 | -2,931 |
| Cash Flow from Operations | 10,522 | 10,770 | 11,117 | 14,174 | 15,581 |
| Cash Flow from Financing | -4,844 | -5,153 | -5,868 | -4,816 | -5,298 |
| Cash Flow per Share | 6.12 | 6.37 | 6.76 | - | - |
| Free Cash Flow | 8,650 | 8,959 | 9,314 | 11,115 | 13,202 |
| Free Cash Flow per Share | 5.25 | 6.09 | 6.53 | 7.21 | - |
| Book Value per Share | 22.28 | 22.99 | 23.46 | - | - |
| Net Debt | 1,787 | -1,498 | -1,677 | -15,860 | - |
| Research & Development Exp. | 2,530 | 2,651 | 2,787 | 2,917 | 3,211 |
| Capital Expenditure | 2,000 | 2,129 | 2,269 | 2,149 | 2,379 |
| Selling, General & Admin. Exp. | 11,028 | 11,494 | 12,163 | 12,708 | 13,386 |
| Shareholder’s Equity | 39,946 | 42,380 | 43,906 | 59,357 | 66,612 |
| Total Assets | 77,215 | 80,103 | 82,228 | 96,686 | 103,579 |
|
Previous Quarter ending 12/31/22 |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 20 | 20 | 19 | 21 | 20 |
| Average Estimate | 0.926 USD | 0.991 USD | 1.081 USD | 4.403 USD | 4.858 USD |
| Year Ago | 1.320 USD | 1.730 USD | 1.430 USD | 5.340 USD | 4.403 USD |
| Publish Date | 1/25/2023 | 4/19/2023 | 7/19/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 17 | 16 | 15 | 20 | 19 |
| Average Estimate | 9,665 USD | 9,673 USD | 9,856 USD | 39,997 USD | 42,175 USD |
| Year Ago | 11,468 USD | 11,895 USD | 11,257 USD | 43,653 USD | 39,997 USD |
| Publish Date | 1/25/2023 | 4/19/2023 | 7/19/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Abbott Laboratories Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Moreland Mary K | 02/28/2023 | 717.00 | 87,224.00 | 100.77 | Sell | No |
| Salvadori Daniel Gesua Sive | 02/28/2023 | 1,085.00 | 119,861.00 | 100.70 | Sell | No |
| MANNING JOSEPH J | 02/28/2023 | 1,339.00 | 62,323.00 | 100.70 | Sell | No |
| WOODGRIFT RANDEL WILLIAM | 02/28/2023 | 1,032.00 | 52,203.00 | 100.70 | Sell | No |
| Funck Robert E | 02/28/2023 | 1,264.00 | 218,237.00 | 100.70 | Sell | No |
| Ginascol John F | 02/28/2023 | 943.00 | 118,380.00 | 100.70 | Sell | No |
| ALLEN HUBERT L | 02/28/2023 | 1,069.00 | 175,959.00 | 100.70 | Sell | No |
| Ahlberg Gregory A | 02/28/2023 | 1,317.00 | 38,420.00 | 100.70 | Sell | No |
| Earnhardt Lisa D | 02/28/2023 | 943.00 | 75,437.00 | 100.70 | Sell | No |
| DALE MICHAEL D | 02/28/2023 | 1,209.00 | 45,133.00 | 100.70 | Sell | No |
| Watkin Jared | 02/28/2023 | 1,198.00 | 71,366.00 | 100.70 | Sell | No |
| Wainer Andrea F | 02/28/2023 | 679.00 | 70,427.00 | 100.70 | Sell | No |
| Tyler Julie L. | 02/28/2023 | 525.00 | 39,162.00 | 100.70 | Sell | No |
| PEDERSON MICHAEL J | 02/27/2023 | 3,522.00 | 63,156.00 | 99.77 | Sell | No |
| Moreland Mary K | 02/27/2023 | 5,926.00 | 87,941.00 | 99.77 | Sell | No |
| Mateus Fernando | 02/27/2023 | 1,024.00 | 22,857.00 | 99.77 | Sell | No |
| Morrone Louis H. | 02/27/2023 | 2,534.00 | 54,748.00 | 99.77 | Sell | No |
| Salvadori Daniel Gesua Sive | 02/27/2023 | 9,002.00 | 120,946.00 | 99.77 | Sell | No |
| Ford Robert B | 02/27/2023 | 30,742.00 | 181,337.00 | 99.77 | Sell | No |
| Wellisch Alejandro D | 02/27/2023 | 3,730.00 | 46,752.00 | 99.77 | Sell | No |
| MANNING JOSEPH J | 02/27/2023 | 5,438.00 | 63,662.00 | 99.77 | Sell | No |
| WOODGRIFT RANDEL WILLIAM | 02/27/2023 | 4,123.00 | 53,235.00 | 99.77 | Sell | No |
| Karam Sammy | 02/27/2023 | 692.00 | 38,092.00 | 99.77 | Sell | No |
| Funck Robert E | 02/27/2023 | 11,500.00 | 219,501.00 | 99.77 | Sell | No |
| Ginascol John F | 02/27/2023 | 6,859.00 | 119,323.00 | 99.77 | Sell | No |
Abbott Laboratories Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | Abbott Laboratories | 1.92 | 1.75 | USD |
| 2021 | Abbott Laboratories | 1.82 | 1.29 | USD |
| 2020 | Abbott Laboratories | 1.53 | 1.40 | USD |
| 2019 | Abbott Laboratories | 1.32 | 1.52 | USD |
| 2018 | Abbott Laboratories | 1.16 | 1.60 | USD |
| 2017 | Abbott Laboratories | 1.07 | 1.88 | USD |
| 2016 | Abbott Laboratories | 1.04 | 2.72 | USD |
| 2015 | Abbott Laboratories | 0.98 | 2.18 | USD |
| 2014 | Abbott Laboratories | 0.90 | 2.00 | USD |
| 2013 | Abbott Laboratories | 0.64 | 1.67 | USD |
| 2012 | Abbott Laboratories | 1.67 | 2.55 | USD |
| 2011 | Abbott Laboratories | 1.92 | 3.41 | USD |
| 2010 | Abbott Laboratories | 1.76 | 3.67 | USD |
| 2009 | Abbott Laboratories | 1.60 | 2.96 | USD |
| 2008 | Abbott Laboratories | 1.44 | 2.70 | USD |
| 2007 | Abbott Laboratories | 1.30 | 2.32 | USD |
| 2006 | Abbott Laboratories | 1.18 | 2.42 | USD |
| 2005 | Abbott Laboratories | 1.10 | 2.79 | USD |
| 2004 | Abbott Laboratories | 1.04 | 2.23 | USD |
| 2003 | Abbott Laboratories | 0.98 | 2.10 | USD |
| 2002 | Abbott Laboratories | 0.94 | 2.35 | USD |
| 2001 | Abbott Laboratories | 0.84 | 1.51 | USD |
| 2000 | Abbott Laboratories | 0.76 | 1.55 | USD |
| 1999 | Abbott Laboratories | 0.68 | 1.87 | USD |
*Yield of the Respective Date
Abbott Laboratories Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.991 USD | Q1 2023 Earnings Release | 04/19/2023 |
| Earnings Report | 1.081 USD | Q2 2023 Earnings Release | 07/19/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 10/18/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 01/24/2024 |
Abbott Laboratories Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 1.030 USD | Q4 2022 Earnings Release | 01/25/2023 |
| Shareholders' Meeting | - | - | 04/29/2022 |
| Press Conference | - | - | 04/20/2022 |
Abbott Laboratories Profile
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1900 and is headquartered in Abbott Park, IL. .
Moody’s Daily Credit Risk Score
Abbott Laboratories Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.13 |
| Fidelity Funds SICAV - World Fund | 10.92 |
| Vanguard Group, Inc. (Subfiler) | 8.54 |
| Capital Research & Management Co. (Global Investors) | 4.42 |
| State Street Corp. | 4.29 |
| Vanguard Total Stock Market Index Fund | 3.09 |
| Capital Research & Management Co. (International Investors) | 3.05 |
| BlackRock Fund Advisors | 2.94 |
| Vanguard 500 Index Fund | 2.33 |
| BlackRock Institutional Trust Co. NA | 2.17 |
| Geode Capital Management LLC | 1.76 |
| Massachusetts Financial Services Co. | 1.43 |
| American Funds Investment Company of America | 1.27 |
| Fidelity 500 Index Fund | 1.10 |
| Norges Bank (13F) | 0.99 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Abbott Laboratories Management
| Name | Job |
|---|---|
| Robert B. Ford | Chairman, President & Chief Executive Officer |
| Gene Huang | Chief Economist & Vice President |
| Robert Emmett Funck | Chief Financial Officer & Executive VP-Finance |
| Claire L. Babineaux-Fontenot | Director |
| Andrea F. Wainer | Executive VP-Rapid & Molecular Diagnostics |
| Mary K. Moreland | Executive Vice President-Human Resources |
| Lisa D. Earnhardt | Executive Vice President-Medical Devices |
| Daniel Gesua Sive Salvadori | Executive Vice President-Nutritional Products |
| John M. Capek | Executive Vice President-Ventures |
| Darren W. McDew | Independent Director |
| Nancy McKinstry | Independent Director |
| Michelle A. Kumbier | Independent Director |
| Glenn Fletcher Tilton | Independent Director |
| Daniel J. Starks | Independent Director |
| John G. Stratton | Independent Director |
| Michael F. Roman | Independent Director |
| Sally E. Blount | Independent Director |
| Robert J. Alpern | Independent Director |
| Paola Gonzalez | Independent Director |
| William A. Osborn | Lead Independent Director |
| Jim Leffelman | Manager-Expense Reporting |
| Karen Chayavirabood | Regional Director-Asia |
| Hubert L. Allen | Secretary, Executive VP & General Counsel |
| Scott J. House | Senior VP-Regulatory & Engineering Services |
| Karen Peterson | Treasurer & Vice President |
| Kathryn S. Collins | Vice President-Commercial Legal Operations |
| Philip P. Boudreau | Vice President-Finance & Controller |
| Melissa Brotz | Vice President-Global Marketing & External Affairs |
| Randel William Woodgrift | Vice President-Global Operations & Cardiovascular |
| David P. Mark | Vice President-Internal Audit |
| Scott Leinenweber | Vice President-Investor Relations |